Confirmed Partners

EXPERTISE PARTNERS

Agilent Technologies

See More:

Agilent Technologies is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward advancing the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. By partnering with Agilent for your CDx development, your drug development program will reap the benefits of an innovative industry leader with more than 20 years’ experience. Agilent launched the first FDA-approved companion diagnostic and continues to deliver world-class CDx products in close collaboration with our pharma partners.

www.agilent.com

Bio-Techne

See More:

Bio-Techne Companion Diagnostics delivers precision medicine services spanning the continuum from biomarker discovery to post-market commercialization of a CDx product. We bring a 20+ year track record of success including the development of over 2700 assays for 570 targets, with over 50 clinical tests built for pharma and 15 CLIA tests. Our multi-omic, platform-agnostic approach, paired with clinical trial sample testing readiness at our CLIA labs and international regulatory expertise, allows us to offer customizable solutions so that a pharma partner can deliver novel treatments to the patients most likely to benefit, faster.

www.bio-techne.com

Caris Life Sciences

See More:

Foundation Medicine

See More:

Grail

See More:

Guardant Health

See More:

Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.

www.guardanthealth.com

Illumina

See More:

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

www.illumina.com

Labcorp

See More:

Clear and confident healthcare decisions begin with questions. At Labcorp, we’re constantly pursuing answers. With unparalleled diagnostics and drug development capabilities, we accelerate innovation and provide insight to improve health and improve lives. Whether you’re a patient, provider, researcher or in the pharmaceutical industry, we’re here for you.

Learn more at www.labcorp.com/ or follow up on LinkedIn and Twitter @Labcorp

Natera

See More:

Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA with high accuracy in identifying MRD and predicting recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types. The test is available for clinical and research use, has been designated by the FDA as a Breakthrough Device, received CE mark. Look deeper at:

www.natera.com/oncology

NEOGenomics

See More:

NeoGenomics specializes in premier cancer solutions. We partner with pharmaceutical clients from discovery to commercialization with our broad oncology testing capabilities powered by in-house scientific expertise and dedicated project support teams. Our clients benefit from our state-of-the-art molecular technology, from whole exome sequencing, whole transcriptome sequencing, HLA typing, and the proprietary MultiOmyx™ high-order multiplexing methodology. We are the trusted experts with over 20 years of experience helping navigate the increasingly complex cancer landscape.

www.neogenomics.com

Oxford BioDynamics

See More:

Personalis

See More:

Personalis, Inc. is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products. ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction to sequencing assays, to data analytics. This makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques. Using this comprehensive approach, we provide genomic data of the highest quality and accuracy to help biopharma drive their immuno-oncology clinical and biomarker discovery programs, thus enabling the rational design and development of effective cancer immunotherapies.

www.personalis.com/

Quest Diagnostics

See More:

Roche

See More:

Tempus

See More:

Veracyte

See More:

PROGRAM PARTNERS

Abcam

See More:

Aignostics

See More:

Aignostics is a spin-off from Charité Berlin, Europe’s largest university hospital, specialising in AI-powered pathology generating novel algorithms, often built on own data, to deliver valuable insights to our clients. Insights which culminate into enhanced understanding of biology of disease such as novel biomarkers/target ID and drug response characteristics. Our proprietary technology has delivered state-of-the-art performance, with algorithms that can be implemented into clinical trials and pulled through into routine diagnostics to improve patient treatment.

www.aignostics.com

Akoya Biosciences

See More:

Almac Diagnostic Services

See More:

Almac Diagnostic Services support global pharma and biotech companies with their biomarker strategies from biomarker discovery through to companion diagnostic partnerships. Almac has clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies. The services offered fall into three main categories:

Genomic Services
Clinical Trial Assays
Companion Diagnostics

www.almacgroup.com

BD Biosciences

See More:

BD Biosciences produces research and clinical tools for the study of single cells to better understand infectious diseases, immunological disorders and cancers. That information can aid in the discovery and development of new drugs and vaccines and the diagnosis and management of diseases, including the development of biomarkers and CDx. Products include the BD FACSLyric™ Flow Cytometer (RUO/IVD), BD FACSDuetTM Sample Preparation System, BD FACSymphony™ A5 SE Cell Analyzer and BD FACSDiscoverTM S8 Cell Sorter, BD Rhapsody™ Single-Cell Analysis System for multiomics, a comprehensive reagent portfolio (RUO/IVD), and informatics solutions with BD FlowJo™ Software. More solutions. More answers. More data you can trust. Discover more with BD at your side.

www.bdbiosciences.com

Biocartis

See More:

With its revolutionary and proprietary Idylla™ platform, Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla™'s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung and liver cancer, as well as for COVID-19 and sepsis.

For more information, visit www.biocartis.com, or follow Biocartis on Twitter, Facebook or LinkedIn.

Biodesix

See More:

BostonGene

See More:

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce overall cost of cancer care. BostonGene’s tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

www.bostongene.com

Burning Rock Dx

See More:

Lunit

See More:

Mission Bio

See More:

Owkin

See More:

Panakeia

See More:

Panakeia provides comprehensive ‘omics' molecular analysis of patient tissues significantly faster and cheaper than other methods. We are creating AI-technology to provide biomarker information directly from H&E-stained tissue images. Panakeia offers reliable results in minutes rather than executing multiple physical tests over several days or weeks. Our offerings enhance both clinical diagnostics and drug development.

www.panakeia.ai

Precede Biosciences

See More:

Q2 Solutions

See More:

Sophia Genetics

See More:

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

www.sophiagenetics.com

CorporateLogo+Message_Vertical_StandardVer_BasicColors_High

Sysmex Inostics, Inc

See More:

ThermoFisher Scientific

See More:

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support precision medicine from translational research to the development of companion diagnostics with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.

www.thermoscientific.com

Genetron

See More:

Genetron Health is a leading precision oncology platform company in China that specializes in the research and application of cancer molecular profiling. We provide early cancer screening, diagnosis and treatment recommendations, continuous disease monitoring and care, and biopharma development services that cover the entire spectrum of cancer management. The Company is committed to applying innovative genomics technology to cancer-related diagnosis and treatment and to ultimately defeating cancer.

en.genetronhealth.com

EXHIBITION PARTNERS

Fulgent Genetics

See More:

Fulgent Genetics is a CLIA and CAP accredited laboratory providing comprehensive genetic testing services, precision medicine solutions, companion diagnostics, and multi-omics service offerings on a global scale. Discover the Power of Precision Medicine and Companion Diagnostics (CDx) with Fulgent Genetics - Your Trusted Global Service Provider for Multi-Omics Solutions

www.fulgentgenetics.com

Angle

See More:

Cell Carta

See More:

Quanterix

See More:

ClearNote Health

See More:

PANEL PARTNERS

Genialis

See More:

Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.

www.genialis.com

Biofidelity

See More:

Leica Biosystems

See More:

Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. In line with our Mission, we have established the following challenge for ourselves: Enable patients to get their diagnosis within 24 hours from biopsy. This is a goal we are striving towards, a goal that will guide our future strategies. This vision aims to decrease the time it takes from biopsy to patient diagnosis, to a 24 hour period. With a presence in every step of the workflow, no other company is positioned to streamline all these steps so that the whole process takes less than 24 hours.

www.leicabiosystems.com

Nucleai

See More:

Veranex

See More:

Veranex brings together best-in-class expertise in product design and engineering, medical device evaluation, clinical development, data management, regulatory, and market access to deliver an integrated and comprehensive solution from concept to commercial success. Our product designers, engineers, market strategists, regulatory professionals, health economists, and clinical development experts help you develop products that deliver sustained value. We partner with you to overcome market and business challenges to ensure your success. With 30+ years of medical product development and commercialization expertise, we have the knowledge and integrated processes to speed you from idea to launch.

www.veranexsolutions.com

Abbott

See More:

Abbott is a global leader in in-vitro diagnostics with one of the broadest portfolios of businesses spanning every segment – point of care, immunoassay, clinical chemistry, hematology, blood screening, molecular and informatics. Molecular Diagnostics has been releasing oncology FISH and PCR assays since 1999. The team at Molecular Diagnostics brings their expertise, passion, and commitment to creating Companion Diagnostics solutions, with well-established CDx development models which embody emerging technology and innovative solutions to help deliver therapeutic success.

www.abbott.com

SPOTLIGHT PARTNERS

Discovery Life Sciences

See More:

Flagship Biosciences

See More:

Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success.

www.flagshipbio.com

Lakeside Life Science

See More:

Saga Diagnostics

See More:

SPOTLIGHT PARTNERS

ZS Associates

See More:

ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products, to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide. To learn more, visit https://www.zs.com/or follow us on Twitter and LinkedIn.

www.zs.com

Medgenome

See More:

September 3 - 6, 2024 I Boston, MA

⭐ The Flagship Meeting for the Clinical Biomarker and CDx Industry